Israel Health News API

{
    "totalArticles": 15026,
    "articles": [
        {
            "id": "637e8fdc98a3ac2e268981dd08673b68",
            "title": "\"It conjures horror images of wide-eyed insanity, foaming at the mouth and a prolonged excruciating death\" All you need to know about rabies",
            "description": "Rabies is one of the most feared diseases in the world with good reason, but thankfully now vaccinations are available",
            "content": "We use the term 'rabid' as a byword for madness and extremely violent behaviour. The very word rabies – Latin for 'rage' – conjures horror images of wide-eyed insanity, victims foaming at the mouth and a prolonged excruciating death – all caused by a... [3878 chars]",
            "url": "https://www.discoverwildlife.com/animal-facts/irabies-guide",
            "image": "https://c02.purpledshub.com/uploads/sites/62/2026/03/rabies.jpg?w=1200",
            "publishedAt": "2026-03-21T02:45:40Z",
            "lang": "en",
            "source": {
                "id": "dabec0e7fc5ef3079adcf6d8a28723a8",
                "name": "BBC Wildlife Magazine",
                "url": "https://www.discoverwildlife.com"
            }
        },
        {
            "id": "352b066e3fc482113259e2756a7a37e4",
            "title": "Eye imaging approach may help distinguish ALS from Alzheimer’s",
            "description": "Eye imaging may help distinguish ALS from Alzheimer’s disease by revealing differences in retinal protein deposits using polarized light.",
            "content": "An analysis of how polarized light interacts with clumps of proteins in the eyes may help differentiate amyotrophic lateral sclerosis (ALS) from Alzheimer’s disease and related conditions, a new study shows.\nIn experiments using post-mortem retinal s... [3130 chars]",
            "url": "https://alsnewstoday.com/news/eye-imaging-approach-help-distinguish-als-alzheimers/",
            "image": "https://alsnewstoday.com/wp-content/uploads/2022/08/EyeTelescope-2.png",
            "publishedAt": "2026-03-20T18:11:15Z",
            "lang": "en",
            "source": {
                "id": "4fb1d5d977743c281d5a932a61dc29a7",
                "name": "ALS News Today",
                "url": "https://alsnewstoday.com"
            }
        },
        {
            "id": "7c08443871ba1a7deeb370f3a9c20a81",
            "title": "AD/PD 2026: Novo Nordisk’s semaglutide fails to demonstrate any benefit for early Alzheimer’s",
            "description": "The results of the EVOKE and EVOKE+ trials were comprehensive in showing oral semaglutide’s lack of clinical efficacy for cognition or function in patients with early Alzheimer’s.",
            "content": "On March 19, at the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, during a symposium focused on oral semaglutide in early Alzheimer’s disease, which includes mild cognitive impairment ... [4640 chars]",
            "url": "https://www.clinicaltrialsarena.com/analyst-comment/ad-pd-2026-novo-nordisk-semaglutide-early-alzheimers/",
            "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2026/03/shutterstock_2440411479-1.jpg",
            "publishedAt": "2026-03-20T16:24:50Z",
            "lang": "en",
            "source": {
                "id": "5fc6401b64c5c4ee117332a7a598b722",
                "name": "Clinical Trials Arena",
                "url": "https://www.clinicaltrialsarena.com"
            }
        }
    ]
}